Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23011772 | 0.89 | KCNK3 (0.82) | MAPTSMN1; SMN2KMT2AMEN1KCNK3 | |
| SCHEMBL7717513 | 0.82 | MEN1 (1.00) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL4001863 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL12496157 | 0.81 | KCNK3 (0.82) | MAPTSMN1; SMN2KMT2AMEN1KCNK3 | |
| SCHEMBL28844856 | 0.81 | KMT2A (0.74) | MAPTSMN1; SMN2KMT2AMEN1KCNK3 | |
| SCHEMBL29684523 | 0.81 | KMT2A (0.74) | MAPTSMN1; SMN2KMT2AMEN1KCNK3 | |
| SCHEMBL2529744 | 0.81 | LMNA (0.69) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL30535354 | 0.81 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL25351544 | 0.81 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL11077480 | 0.80 | KCNK3 (0.78) | MAPTSMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057021-B | S-triazine compound, preparation method and application thereof | 中国药科大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-111057021-A | S-triazine compound and its preparing method and use | 中国药科大学 | 2020-04-24 | — | — | CN | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | RRS1, RPS3, ADRM1 | MAPT 3461/4885SMN1; SMN2 3677/4885KMT2A 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.